Acer therapeutics announces $2.675 million registered direct offering priced at-the-market under nasdaq rules

Newton, mass., march 22, 2023 (globe newswire) -- acer therapeutics inc. (nasdaq: acer ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the company's common stock (or common stock equivalents) at a purchase price of $0.916 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under nasdaq rules. in addition, in a concurrent private placement, the company will issue warrants to purchase up to 2,920,306 shares of common stock. the warrants will have an exercise price of $0.791 per share, will be exercisable immediately following issuance and have a term of five and one-half years from the issuance date.
ACER Ratings Summary
ACER Quant Ranking